<DOC>
	<DOC>NCT01821066</DOC>
	<brief_summary>A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of PD-0332991 in healthy male volunteers.</brief_summary>
	<brief_title>A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Healthy male between the ages of 18 and 55 years of age inclusive Body mass index (BMI) between 17.5 and 30.5 kg/m2 Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures a positive urine drug screen a supine systolic blood pressure &gt;140 mm Hg, or diastolic blood pressure &gt;90 mm H. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PD-0332991</keyword>
	<keyword>palbociclib</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>drug-drug interaction (DDI) study</keyword>
</DOC>